title: Clinical outcomes and management of inflammatory bowel disease in the older patient.
abstract: The management of inflammatory bowel disease in the older patient extends beyond the gastrointestinal tract. Pre-existing comorbidities, polypharmacy, functional status and physical reserve can impact disease course, response to therapy and quality of life. Current therapeutic endpoints may not be as immediately applicable to the older IBD patient at higher risk for adverse outcomes. This review focuses on the latest studies addressing the natural history, clinical course and therapeutic outcomes among the older IBD cohort.
authors: Meyerhoff Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, 1830 East Monument Street, Suite 430, Baltimore, MD, 21287, USA. christina.ha@jhmi.edu
authors: Christina Y
authors: CY
authors: Ha
authors: Seymour
authors: S
authors: Katz
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000453:epidemiology*; D015897:Comorbidity; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D019338:Polypharmacy; D012878:Skin Neoplasms / Q000453:epidemiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha